Where Will Syros Pharmaceuticals Inc (SYRS) Stock Go Next After It Is Lower By 19.30% in a Week?

The market has been down on Syros Pharmaceuticals Inc (SYRS) stock recently. SYRS gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Syros Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SYRS!

See Full SYRS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With SYRS Stock Today?

Syros Pharmaceuticals Inc (SYRS) stock is higher by 2.22% while the S&P 500 is lower by -0.1% as of 10:14 AM on Tuesday, Oct 17. SYRS has gained $0.05 from the previous closing price of $2.25 on volume of 5,709 shares. Over the past year the S&P 500 has gained 18.79% while SYRS is lower by -60.41%. SYRS lost -$0.26 per share in the over the last 12 months. To screen for more stocks like Syros Pharmaceuticals Inc click here.

More About Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States. Click Here to get the full Stock Report for Syros Pharmaceuticals Inc stock.